SAN Sanofi

Sanofi: Information concerning the total number of voting rights and shares - September 2021

Sanofi: Information concerning the total number of voting rights and shares - September 2021

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi

a French société anonyme with a registered share capital of 2,526,866,030 €

Registered office : 54, rue La Boétie - 75008 Paris - France

Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date  



Total number of

issued shares



  		Number of real

voting rights

(excluding treasury shares) 		Theoretical number of

voting rights

(including treasury shares)*
September 30, 2021 1,263,471,400 1,412,107,775 1,420,360,348

* Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi under « Regulated Information in France »:

Investor Relations Department

Europe Tel: 45      US Tel: 0

e-mail:



 



Media Relations Department

Tel: 46

e-mail:



 

 

Attachment



EN
27/10/2021

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Sanofi: Information concerning the total number of voting rights and s...

Sanofi: Information concerning the total number of voting rights and shares – October 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry u...

2h / 10m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Sanofi: Informations relatives au nombre de droits de vote et d'action...

Sanofi: Informations relatives au nombre de droits de vote et d'actions – Octobre 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 454 937 946 eurosSiège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris acti...

2h / 10m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study m...

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion, and nasal polyps in patients a...

November 7, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi...

Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique... ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique ; la demande supplémentaire de licence de mise sur le marché (sBLA) a été acceptée pour examen prioritaire par la FDA Les données de phase 3 qui v...

November 7, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press release: Sanofi successfully prices USD 3 billion of bond issue

Press release: Sanofi successfully prices USD 3 billion of bond issue Sanofi successfully prices USD 3 billion of bond issue   Paris, France – October 28, 2025 - Sanofi announces that it has successfully priced its offering of $3 billion of notes across 5 tranches:  $400 million fixed rate notes, due November 2027, bearing interest at a rate of 3.75%. $500 million floating rate notes, due November 2027, bearing interest at compounded SOFR plus 0.46%. $400 million fixed rate notes, due November 2028, bearing interest at a rate of 3.80%. $500 million floating rate notes, due November 202...

October 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch